Alpha Teknova, Inc. TKNO R2KPHARMA
Company Overview
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Recent Developments
- Dec 2025 Revenue of $40.52M (+7.4% YoY); net profit $-17.26M.
- Trailing 12 Months Year-on-year growth — revenue +13.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.30% |
| 1 Year: | 13.10% |
Stock Price Performance
| 1 Year: | +44.36% |
| 6 Months: | +233.89% |
| 3 Months: | +54.50% |
| 1 Month: | +7.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TKNO Alpha Teknova, Inc. R2KPHARMA | 7.04 | -22.71 | $377.97M | 0.00% | -17.67% | -23.92% | 5.30% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 8.98M | 9.08M | 8.31M | 9.39M | 11.15M | 11.69M | 10.69M | 9.12M | 11.53M | 8.17M | 9.29M | 9.61M | 9.58M | 9.79M | 10.29M | 10.45M | 11.08M | 12.19M |
| Gross Profit | 3.47M | 5.09M | 5.03M | 3.35M | 4.26M | 5.35M | 5.25M | 4.77M | 2.42M | 5.07M | 1.47M | 2.21M | 2.80M | 90.00K | 3.01M | 3.98M | 3.21M | 3.78M | 4.88M |
| Operating Income | 704.00K | 2.15M | -828.00K | -2.53M | -3.89M | -5.84M | -6.63M | -22.95M | -8.95M | -7.00M | -8.76M | -7.99M | -5.10M | -7.43M | -4.96M | -3.39M | -4.02M | -4.30M | -2.89M |
| Net Income | 512.00K | 1.53M | -655.00K | -2.25M | -3.25M | -5.50M | -6.20M | -22.47M | -8.82M | -7.15M | -10.15M | -8.10M | -5.36M | -7.57M | -4.64M | -3.57M | -4.29M | -4.55M | -3.17M |
| Diluted EPS | 0.02 | 0.07 | - | -0.52 | -0.12 | -0.20 | -0.22 | -0.80 | -0.31 | -0.25 | -0.34 | -0.20 | -0.13 | -0.15 | -0.09 | -0.07 | -0.08 | -0.08 | -0.06 |
| R&D Expense | 341.00K | 358.00K | 700.00K | 851.00K | 1.37M | 2.01M | 1.93M | 1.93M | 1.40M | 1.46M | 1.40M | 860.00K | 678.00K | 627.00K | 552.00K | 581.00K | 542.00K | 609.00K | 554.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 31.30M | 36.89M | 41.42M | 36.68M | 37.74M | 40.52M |
| Gross Profit | 17.75M | 17.62M | 17.48M | 10.30M | 7.23M | 13.44M |
| Operating Income | 4.66M | -12.01M | -49.66M | -35.56M | -26.15M | -16.98M |
| Net Income | 3.57M | -9.80M | -47.47M | -36.78M | -26.75M | -17.26M |
| Diluted EPS | 0.16 | -0.61 | -1.69 | -1.16 | -0.57 | -0.32 |
| R&D Expense | 1.51M | 4.31M | 7.74M | 5.57M | 2.76M | 2.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 62.91M | 166.51M | 152.26M | 128.59M | 118.77M | 103.58M |
| Total Equity | 12.91M | 16.77M | 143.20M | 99.89M | 90.04M | 82.39M | 68.78M |
| Cash & Equivalents | 4.14M | 3.31M | 87.52M | 42.24M | 28.48M | 3.71M | 5.91M |
| Long Term Debt | - | 0 | 11.87M | 21.98M | 13.25M | 9.44M | 13.12M |
| Total Liabilities | - | 10.51M | 23.31M | 52.38M | 38.55M | 36.38M | 34.81M |
| Current Liabilities | - | 3.96M | 7.74M | 10.88M | 8.88M | 11.21M | 7.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.50M | - | -27.40M | -18.81M | -12.39M | -8.65M |
| Investing Cash Flow | -1.74M | - | -28.15M | -7.74M | -27.27M | 10.70M |
| Financing Cash Flow | -1.60M | - | 10.27M | 12.80M | 14.89M | 151.00K |
| Capital Expenditure | -5.47M | - | -28.15M | -7.93M | -1.12M | -1.15M |
| Free Cash Flow | -2.96M | - | -55.55M | -26.75M | -13.52M | -9.79M |
| Net Change in Cash | - | - | -45.28M | -13.75M | -24.78M | 2.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating Margin % | 14.9% | -32.5% | -119.9% | -96.9% | -69.3% | -41.9% |
| Net Margin % | 11.4% | -26.6% | -114.6% | -100.3% | -70.9% | -42.6% |
| ROE % | 21.3% | -6.8% | -47.5% | -40.9% | -32.5% | -25.1% |
| ROCE % | 7.9% | -7.6% | -35.1% | -29.7% | -24.3% | -17.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Royce & Associates LP | 3.10% | 1.66M | $11.83M |
| 2 | Vanguard Capital Management LLC | 3.01% | 1.61M | $11.49M |
| 3 | Roubaix Capital, LLC | 2.95% | 1.58M | $11.25M |
| 4 | Blackrock Inc. | 1.64% | 879.79K | $6.26M |
| 5 | UBS Group AG | 1.18% | 631.97K | $4.50M |
| 6 | Conestoga Capital Advisors, LLC | 0.59% | 314.55K | $2.24M |
| 7 | Geode Capital Management, LLC | 0.58% | 311.82K | $2.22M |
| 8 | Bank of America Corporation | 0.48% | 255.76K | $1.82M |
| 9 | Goldman Sachs Group Inc | 0.32% | 172.02K | $1.22M |
| 10 | State Street Corporation | 0.31% | 164.88K | $1.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TKNO
(TKNO) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPVlljRmMwZUEyVFA0b2lqLUhkcUtibnhSeWJ6YTlRNE9wMVBEbldqWmw3LXhrNF9LbmhVNTFwaWcydzBaVFpsMi16NEduQUIzQ1dMNDBsUUhGem5Jdm56b2ZsNjRGNzlBbzZ3c01wTlRiSUdiVVJGMW9kQ2l0dmZINzc3VWloUnlycHdua0…
TKNO Stock Price and Chart — NASDAQ:TKNO - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE5OaTQ3VWxwOHJIWHVYTERpcjJNX0ZFa0NmYzhnOE5wR3dvS0Fkd3pySThyeV9zRGFGbnJnRWJ3MDJEeVprak5TXzJBYjJaWkxycERZM2MzOFd3LWVh?oc=5" target="_blank">TKNO Stock Price and Chart — NASDAQ:TKNO</a…
Earnings To Watch: Alpha Teknova Inc (TKNO) Q2 2026 -- GF Value Sees 24% Downside - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOdVd3ejBsOWR3b3M3bGpiUTA0MDNrZUFpS3htd0daUkd2cDh6aU1WNENMR0N4b0R2S01Ba3VxdU1xNDlUZU9UcExwSWEwZ2lvWm9YVDFWbmpURlVNYmo1dTJzTU05VkFiWVZUVEozc3B3dGtOSU92NTBma1ljcGp2M0NkVnF6Sm1NdzQ1T2…
Should I buy Alpha Teknova (TKNO) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE1kUXppaW1jM0JJek1jZ0QzQVNieG9nR05jTlA4N1RNeGlLSEdiT0FLSURwb3ZCNXNaaTJxeDQzeFlEc2NpcUJ2S0h5MlpZMGpHb0pYM2ZESVlSOWRpX3NhYkc3cWdrbU1OdGxHRA?oc=5" target="_blank">Should I buy Alpha Te…
TKNO | Alpha Teknova, Inc. Common Financials - Revenue Breakdown - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5WZDdtMnBldlBHYnFJTFFYdWoyZDFvWGduNWNuMjV6SkIyamprSWJoWEUwQXU2V2JWQmdlUXV6a0k4ellZcUpLUmtNUVlRVW5xZHBPdndDMUlOUk1oX3Z2Sm1ORXpKZWpSYWVSQnVBOGoxRXB6QWNJ?oc=5" target="_blank">TKNO | …
Alpha Teknova: Ample Manufacturing Capacity At A High Premium (NASDAQ:TKNO) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOZVdnN2VjUk9lRG1SYmhSeHdLN1oycHFLX0VibGdnYUJfbjBHTnd1a2hlMGhJTk9xQ0NaWmt6RUNxT21JQllWUXZta0dOZGQzdHBkLW9UU3dESGMtLThGdUVnYngtN0ZxWlVaTkpCbTctalU3N0kzNy1lZVV6a0tyOENUaHlhUEJXUExQeF…
TKNO — Frequently Asked Questions
What is the current share price of Alpha Teknova, Inc. (TKNO)?
As of 2026-09-07 16:24 PDT, Alpha Teknova, Inc. (TKNO) trades at $7.04 on NasdaqGM. Its 52-week range is $1.99 to $7.46.
What is the market capitalisation of TKNO?
Alpha Teknova, Inc. (TKNO) has a market capitalisation of $377.97M on NasdaqGM.
What is the P/E ratio of TKNO?
TKNO trades at a trailing price-to-earnings (P/E) ratio of -22.71. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.03.
What is the return on equity (ROE) of TKNO?
TKNO has a return on equity (ROE) of -23.92%. Its return on capital employed (ROCE) is -17.67%.
Is TKNO a good stock to buy?
This page provides a data-driven analysis of Alpha Teknova, Inc. (TKNO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.